Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indatuximab ravtansine - Biotest AG

Drug Profile

Indatuximab ravtansine - Biotest AG

Alternative Names: Anti-myeloma monoclonal antibody-DM4 immunoconjugate BT-062; BT-062; Maytansinoid-conjugated anti-myeloma monoclonal antibody BT-062; N2'-Deacetyl-N2'-[4-Methyl-4-(Oxobuthyldithio)-1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal Antibody; nBT062

Latest Information Update: 29 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Multiple myeloma

Most Recent Events

  • 29 Jan 2018 Indatuximab ravtansine is still at phase II development stage for Bladder cancer and Breast cancer in Germany and Belgium (IV) (Biotest pipeline, January 2018)
  • 29 Jan 2018 Indatuximab ravtansine is still at phase II development stage for Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (IV) (Biotest pipeline, January 2018)
  • 04 Aug 2017 Biotest completes a phase I/II trial in Bladder cancer and Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium, Germany (IV) (EudraCT2013-003252-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top